A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy

Trial Profile

A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Ixazomib (Primary) ; Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Alliance
  • Most Recent Events

    • 20 Jun 2017 Status changed from recruiting to suspended because DSMB recommendation to revise study design
    • 04 Oct 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2017.
    • 02 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top